1. Minocycline delays but does not attenuate the course of experimental autoimmune encephalomyelitis in Streptococcus pneumoniae-infected mice
- Author
-
Joachim Gerber, Annette Spreer, Marco Prinz, Helmut Eiffert, Isabel Herrmann, Roland Nau, and Markus Kellert
- Subjects
Lipopolysaccharides ,Microbiology (medical) ,Encephalomyelitis, Autoimmune, Experimental ,medicine.drug_class ,Antibiotics ,Minocycline ,Biology ,medicine.disease_cause ,Pneumococcal Infections ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Streptococcus pneumoniae ,medicine ,Animals ,Pharmacology (medical) ,030304 developmental biology ,Antibacterial agent ,Pharmacology ,0303 health sciences ,Pneumolysin ,Protein synthesis inhibitor ,Ceftriaxone ,Experimental autoimmune encephalomyelitis ,medicine.disease ,Anti-Bacterial Agents ,3. Good health ,Mice, Inbred C57BL ,Teichoic Acids ,Infectious Diseases ,Immunology ,Female ,Rifampin ,030217 neurology & neurosurgery ,medicine.drug - Abstract
OBJECTIVES Experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS), can be aggravated by a mild Streptococcus pneumoniae infection. This study was performed to assess whether treatment with antibiotics inhibiting bacterial protein synthesis reduces the detrimental effect of infection on the course of EAE. METHODS In vitro, release of proinflammatory pneumococcal products was studied by enzyme immunoassay and western blot. Seven days after induction of EAE (prior to the onset of symptoms) mice were infected intraperitoneally with S. pneumoniae and treated either with the inhibitors of bacterial protein synthesis minocycline or rifampicin, or with the beta-lactam ceftriaxone. RESULTS During bacterial killing in vitro, minocycline and rifampicin released lower quantities of proinflammatory bacterial products from S. pneumoniae than ceftriaxone. Mice treated with minocycline developed symptoms of EAE 1 day later than mice treated with ceftriaxone. Neither minocycline nor rifampicin therapy, however, reduced the severity of EAE in comparison with ceftriaxone treatment. CONCLUSIONS Although statistically significant (P = 0.04), a delay of 1 day in the onset of symptoms of EAE after minocycline treatment is of minor clinical relevance. These data do not support the hypothesis of superiority of a bacterial protein synthesis inhibitor over a beta-lactam antibiotic for the treatment of concomitant infections during the latent phase of EAE or MS.
- Published
- 2006
- Full Text
- View/download PDF